Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01449240 · ClinicalTrials.gov registry record
Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
A clinical trial, sponsored by Shire.
- Completed
- Registry status
- 10
- Enrollment target
NCT01449240: Completed study, sponsored by Shire.
NCT01449240 is a clinical trial that has completed, run by Shire. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01449240 has completed, sponsored by Shire.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The purpose of the study is to collect data on CSF biomarkers in patients with Hunter Syndrome that would serve as reference data for comparison with cognitively impaired patients with Hunter syndrome, patients with other lysosomal storage diseases, or other diseases with CNS involvement.
Primary Outcome
The concentration of total GAG, including heparan sulfate (HS) and dermatan sulfate (DS) oligosaccharides, in CSF was measured using an enzymatic assay.
Interventions
- OTHER No treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2012-11-12 |
| Est. Completion | 2013-12-20 |
What the finished NCT01449240 record still lists
NCT01449240 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No treatment is the first listed.
NCT01449240 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01449240 about?
NCT01449240 is a clinical study titled "Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome". The purpose of the study is to collect data on CSF biomarkers in patients with Hunter Syndrome that would serve as reference data for comparison with cognitively impaired patients with Hunter syndrome, patients with other lysosomal storage diseases, or other diseases with CNS involvement.
What is the current status of trial NCT01449240?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2012-11-12. Estimated completion is 2013-12-20.
What interventions are being tested in trial NCT01449240?
The interventions under investigation include: No treatment (OTHER).
Who is sponsoring clinical trial NCT01449240?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI